Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Octreotide for non-variceal gastrointestinal bleeding
IRCT20260806070556N1Phase 3Not yet recruiting
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Nov 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in gastrointestinal bleeding comparing Octreotide + pantoprazole with Placebo + pantoprazole (2 arms). Primary endpoints: Requirement for blood transfusion, Length of hospital stay and 1 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
octreotidepantoprazole
03
Conditions
gastrointestinal bleeding
Beyond the preview
Go deeper on IRCT20260806070556N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260806070556N1.